BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:59 PM
 | 
Oct 25, 2012
 |  BC Extra  |  Top Story

FDA discloses concerns on Novo insulins

FDA is concerned about the cardiovascular safety of two Novo Nordisk A/S (CSE:NVO; NYSE:NVO) insulin products under review for Type I and II diabetes, according to a document made public ahead of the Nov. 8 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee to discuss NDAs...

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >